These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 28614910)

  • 21. Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy.
    Shi Z; Das S; Okwan-Duodu D; Esiashvili N; Flowers C; Chen Z; Wang X; Jiang K; Nastoupil LJ; Khan MK
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):569-77. PubMed ID: 23540349
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Visceral adipose tissue is prognostic for survival of diffuse large B cell lymphoma treated with frontline R-CHOP.
    Shin DY; Kim A; Byun BH; Moon H; Kim S; Ko YJ; Kim MJ; Lee HR; Kang HJ; Na II; Park S; Lee SS; Yang SH
    Ann Hematol; 2016 Feb; 95(3):409-16. PubMed ID: 26658607
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
    Récher C; Coiffier B; Haioun C; Molina TJ; Fermé C; Casasnovas O; Thiéblemont C; Bosly A; Laurent G; Morschhauser F; Ghesquières H; Jardin F; Bologna S; Fruchart C; Corront B; Gabarre J; Bonnet C; Janvier M; Canioni D; Jais JP; Salles G; Tilly H;
    Lancet; 2011 Nov; 378(9806):1858-67. PubMed ID: 22118442
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Favourable outcomes of poor prognosis diffuse large B-cell lymphoma patients treated with dose-dense Rituximab, high-dose Methotrexate and six cycles of CHOP-14 compared to first-line autologous transplantation.
    Strüßmann T; Fritsch K; Baumgarten A; Fietz T; Engelhardt M; Mertelsmann R; Ihorst G; Duyster J; Finke J; Marks R
    Br J Haematol; 2017 Sep; 178(6):927-935. PubMed ID: 28643323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
    Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
    Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group.
    Pfreundschuh M; Poeschel V; Zeynalova S; Hänel M; Held G; Schmitz N; Viardot A; Dreyling MH; Hallek M; Mueller C; Wiesen MH; Witzens-Harig M; Truemper L; Keller U; Rixecker T; Zwick C; Murawski N
    J Clin Oncol; 2014 Dec; 32(36):4127-33. PubMed ID: 25403207
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.
    Delarue R; Tilly H; Mounier N; Petrella T; Salles G; Thieblemont C; Bologna S; Ghesquières H; Hacini M; Fruchart C; Ysebaert L; Fermé C; Casasnovas O; Van Hoof A; Thyss A; Delmer A; Fitoussi O; Molina TJ; Haioun C; Bosly A
    Lancet Oncol; 2013 May; 14(6):525-33. PubMed ID: 23578722
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
    Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Statin use has negative clinical impact on non-germinal center in patients with diffuse large B cell lymphoma in rituximab era.
    Song MK; Chung JS; Lee GW; Cho SH; Hong J; Shin DY; Shin HJ
    Leuk Res; 2015 Feb; 39(2):211-5. PubMed ID: 25541029
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Prognostic impact of anthracyclines in the treatment of aggressive lymphoma in patients over 70 years].
    Ancochea Á; Salar A; García-Pallarols F; Gimeno E; Fernández-Rodriguez C; Sánchez-González B
    Med Clin (Barc); 2015 Jun; 144(12):544-7. PubMed ID: 25110180
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.
    Johnston PB; LaPlant B; McPhail E; Habermann TM; Inwards DJ; Micallef IN; Colgan JP; Nowakowski GS; Ansell SM; Witzig TE
    Lancet Haematol; 2016 Jul; 3(7):e309-16. PubMed ID: 27374464
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD5 expression correlates with inferior survival and enhances the negative effect of p53 overexpression in diffuse large B-cell lymphoma.
    Zhao P; Li L; Zhou S; Qiu L; Qian Z; Liu X; Meng B; Zhang H
    Hematol Oncol; 2019 Oct; 37(4):360-367. PubMed ID: 31359442
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).
    Pfreundschuh M; Schubert J; Ziepert M; Schmits R; Mohren M; Lengfelder E; Reiser M; Nickenig C; Clemens M; Peter N; Bokemeyer C; Eimermacher H; Ho A; Hoffmann M; Mertelsmann R; Trümper L; Balleisen L; Liersch R; Metzner B; Hartmann F; Glass B; Poeschel V; Schmitz N; Ruebe C; Feller AC; Loeffler M;
    Lancet Oncol; 2008 Feb; 9(2):105-16. PubMed ID: 18226581
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Benefit of consolidative radiation therapy for primary bone diffuse large B-cell lymphoma.
    Tao R; Allen PK; Rodriguez A; Shihadeh F; Pinnix CC; Arzu I; Reed VK; Oki Y; Westin JR; Fayad LE; Medeiros LJ; Dabaja B
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):122-9. PubMed ID: 25754633
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The importance of Myd88 L265P mutation, clinical and immunohistochemical prognostic factors for the survival of patients with diffuse large B-cell non-Hodgkin lymphoma treated by immunochemotherapy in southeast Serbia.
    Tadic L; Marjanovic G; Macukanovic-Golubovic L; Krstic M; Jevtovic-Stoimenov T; Kostov M; Smelcerovic Z; Stojanovic M
    J BUON; 2016; 21(5):1259-1267. PubMed ID: 27837631
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.
    Nowakowski GS; LaPlant B; Macon WR; Reeder CB; Foran JM; Nelson GD; Thompson CA; Rivera CE; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Ansell SM; Gascoyne RD; Habermann TM; Witzig TE
    J Clin Oncol; 2015 Jan; 33(3):251-7. PubMed ID: 25135992
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The impact of Fc-γ receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab.
    Ahlgrimm M; Pfreundschuh M; Kreuz M; Regitz E; Preuss KD; Bittenbring J
    Blood; 2011 Oct; 118(17):4657-62. PubMed ID: 21900198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A success story: how a single targeted-therapy molecule impacted on treatment and outcome of diffuse large B-cell lymphoma.
    Mian M; Augustin F; Kocher F; Gunsilius E; Willenbacher W; Zabernigg A; Zangerl G; Oexle H; Schreieck S; Schnallinger M; Fiegl M
    Anticancer Res; 2014 May; 34(5):2559-64. PubMed ID: 24778077
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients.
    Park YH; Lee JJ; Ryu MH; Kim SY; Kim DH; Do YR; Lee KH; Oh SJ; Kim YK; Suh CW; Heo DS; Ryoo BY; Kim JK; Song HS; Lee WS; Kim HJ; Bang YJ; Yang SH; Sohn SK; Kang YK;
    Ann Hematol; 2006 Apr; 85(4):257-62. PubMed ID: 16416337
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients.
    Pfreundschuh M; Murawski N; Zeynalova S; Ziepert M; Loeffler M; Hänel M; Dierlamm J; Keller U; Dreyling M; Truemper L; Frickhofen N; Hünerlitürkoglu AN; Schmitz N; Pöschel V; Rixecker T; Berdel C; Rübe C; Held G; Zwick C
    Br J Haematol; 2017 Nov; 179(3):410-420. PubMed ID: 28990173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.